Please enable JavaScript to continue using this application.

Compare $LITS vs $MGX | Chartloom

Compare

$LITS vs $MGX

Lite Strategy Inc · Metagenomi Therapeutics Inc

LITS

Lite Strategy Inc

MGX

Metagenomi Therapeutics Inc

Compare $LITS vs $MGX

Comparing Lite Strategy Inc and Metagenomi Therapeutics Inc

LITSLite Strategy Inc

MGXMetagenomi Therapeutics Inc

LITSLite Strategy Inc

Market cap

$43M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-17.5%

52W performance

-49.2%

FCF yield

-21.1%

MGXMetagenomi Therapeutics Inc

Market cap

$38M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.83x

Rev growth (TTM)

-50.7%

YTD performance

-40.1%

52W performance

-68.7%

FCF yield

-227.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LITS

MGX

Detailed metrics comparison

LITS

Lite Strategy Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

LITS$43M

MGX$38M

Enterprise Value

LITS$38M

MGX$-1M

Price

LITS$1.27

MGX$1.00

P/E Ratio

LITSN/A

MGXN/A

P/S Ratio

LITS0.40x

MGX2.72x

EV/Sales

LITS0.00x

MGX-0.10x

EV/EBITDA

LITS0.00x

MGX0.00x

P/B Ratio

LITS1.01x

MGX0.34x

P/FCF Ratio

LITSN/A

MGXN/A

EV/FCF

LITS-4.11x

MGX0.02x

PEG Ratio

LITSN/A

MGXN/A

Forward P/E (NTM)

LITSN/A

MGXN/A

Forward P/S (NTM)

LITSN/A

MGX3.83x

Revenue (TTM)

LITS$0

MGX$14M

Revenue Growth (YoY)

LITSN/A

MGX-50.7%

Forward Rev Growth

LITS0.0%

MGX30.0%

Gross Margin (TTM)

LITS100.0%

MGX0.0%

Operating Margin (TTM)

LITS34.9%

MGX0.0%

EBITDA Margin (TTM)

LITS0.0%

MGX-491.3%

Net Margin (TTM)

LITS39.0%

MGX-477.5%

FCF Margin (TTM)

LITSN/A

MGX-620.9%

Net Income (TTM)

LITS$-34M

MGX$-66M

FCF (TTM)

LITS$-9M

MGX$-86M

EPS (TTM)

LITS$0.00

MGX$0.00

ROE (TTM)

LITS-6886.0%

MGX-5123.0%

ROA (TTM)

LITS-6748.0%

MGX-3662.0%

ROIC (TTM)

LITS-6886.0%

MGX-5123.0%

Cash

LITS$6M

MGX$39M

Debt

LITS$0

MGX$0

Net Cash/Debt

LITS$6M

MGX$39M

Current Ratio (TTM)

LITS5.74x

MGX4.50x

Quick Ratio (TTM)

LITS5.34x

MGX4.37x

Debt/Equity (TTM)

LITS0.00x

MGX0.00x

Debt/Assets (TTM)

LITS0.0%

MGX0.0%

Interest Coverage (TTM)

LITSN/A

MGXN/A

Net Debt/EBITDA (TTM)

LITS0.00x

MGX0.00x

Beta

LITS0.06

MGX0.68

52W Performance

LITS-49.2%

MGX-68.7%

YTD Performance

LITS-17.5%

MGX-40.1%

% from 52W High

LITS-57.2%

MGX-74.7%

% from 52W Low

LITS84.4%

MGX4.2%

Asset Turnover (TTM)

LITS0.84x

MGX0.10x

FCF Yield (TTM)

LITS-21.1%

MGX-227.9%

Earnings Yield (TTM)

LITS-79.7%

MGX-175.2%

Dividend Yield (TTM)

LITSN/A

MGXN/A

Rule of 40

LITS0.0

MGX-671.6

EV/GP/RG

LITSN/A

MGXN/A

Ticker research

View LITS research View MGX research

Metric	LITS Lite Strategy Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$43M	$38M
Enterprise Value	$38M	$-1M
Price	$1.27	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	0.40x	2.72x
EV/Sales	0.00x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.01x	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.11x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$0	$14M
Revenue Growth (YoY)	N/A	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	34.9%	0.0%
EBITDA Margin (TTM)	0.0%	-491.3%
Net Margin (TTM)	39.0%	-477.5%
FCF Margin (TTM)	N/A	-620.9%
Net Income (TTM)	$-34M	$-66M
FCF (TTM)	$-9M	$-86M
EPS (TTM)	$0.00	$0.00
ROE (TTM)	-6886.0%	-5123.0%
ROA (TTM)	-6748.0%	-3662.0%
ROIC (TTM)	-6886.0%	-5123.0%
Financial Health
Cash	$6M	$39M
Debt	$0	$0
Net Cash/Debt	$6M	$39M
Current Ratio (TTM)	5.74x	4.50x
Quick Ratio (TTM)	5.34x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.06	0.68
52W Performance	-49.2%	-68.7%
YTD Performance	-17.5%	-40.1%
% from 52W High	-57.2%	-74.7%
% from 52W Low	84.4%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.84x	0.10x
FCF Yield (TTM)	-21.1%	-227.9%
Earnings Yield (TTM)	-79.7%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View LITS research	View MGX research

Valuation

P/S Ratio

LITS

0.40x

MGX

2.72x

EV/FCF

LITS

-4.11x

MGX

0.02x

Growth & revenue

Revenue Growth TTM

MGX

-50.7%

Forward Revenue Growth

MGX

30.0%

LITS

0.0%

Profitability & performance

Gross Margin

LITS

100.0%

MGX

0.0%

ROE

MGX

-5123.0%

LITS

-6886.0%

FCF Yield %

LITS

-21.1%

MGX

-227.9%

52-Week Performance

LITS

-49.2%

MGX

-68.7%

Detailed metrics comparison

LITS

Lite Strategy Inc

MGX

Metagenomi Therapeutics Inc

Market Cap

LITS$43M

MGX$38M

Enterprise Value

LITS$38M

MGX$-1M

Price

LITS$1.27

MGX$1.00

P/E Ratio

LITSN/A

MGXN/A

P/S Ratio

LITS0.40x

MGX2.72x

EV/Sales

LITS0.00x

MGX-0.10x

EV/EBITDA

LITS0.00x

MGX0.00x

P/B Ratio

LITS1.01x

MGX0.34x

P/FCF Ratio

LITSN/A

MGXN/A

EV/FCF

LITS-4.11x

MGX0.02x

PEG Ratio

LITSN/A

MGXN/A

Forward P/E (NTM)

LITSN/A

MGXN/A

Forward P/S (NTM)

LITSN/A

MGX3.83x

Revenue (TTM)

LITS$0

MGX$14M

Revenue Growth (YoY)

LITSN/A

MGX-50.7%

Forward Rev Growth

LITS0.0%

MGX30.0%

Gross Margin (TTM)

LITS100.0%

MGX0.0%

Operating Margin (TTM)

LITS34.9%

MGX0.0%

EBITDA Margin (TTM)

LITS0.0%

MGX-491.3%

Net Margin (TTM)

LITS39.0%

MGX-477.5%

FCF Margin (TTM)

LITSN/A

MGX-620.9%

Net Income (TTM)

LITS$-34M

MGX$-66M

FCF (TTM)

LITS$-9M

MGX$-86M

EPS (TTM)

LITS$0.00

MGX$0.00

ROE (TTM)

LITS-6886.0%

MGX-5123.0%

ROA (TTM)

LITS-6748.0%

MGX-3662.0%

ROIC (TTM)

LITS-6886.0%

MGX-5123.0%

Cash

LITS$6M

MGX$39M

Debt

LITS$0

MGX$0

Net Cash/Debt

LITS$6M

MGX$39M

Current Ratio (TTM)

LITS5.74x

MGX4.50x

Quick Ratio (TTM)

LITS5.34x

MGX4.37x

Debt/Equity (TTM)

LITS0.00x

MGX0.00x

Debt/Assets (TTM)

LITS0.0%

MGX0.0%

Interest Coverage (TTM)

LITSN/A

MGXN/A

Net Debt/EBITDA (TTM)

LITS0.00x

MGX0.00x

Beta

LITS0.06

MGX0.68

52W Performance

LITS-49.2%

MGX-68.7%

YTD Performance

LITS-17.5%

MGX-40.1%

% from 52W High

LITS-57.2%

MGX-74.7%

% from 52W Low

LITS84.4%

MGX4.2%

Asset Turnover (TTM)

LITS0.84x

MGX0.10x

FCF Yield (TTM)

LITS-21.1%

MGX-227.9%

Earnings Yield (TTM)

LITS-79.7%

MGX-175.2%

Dividend Yield (TTM)

LITSN/A

MGXN/A

Rule of 40

LITS0.0

MGX-671.6

EV/GP/RG

LITSN/A

MGXN/A

Ticker research

View LITS research View MGX research

Metric	LITS Lite Strategy Inc	MGX Metagenomi Therapeutics Inc
Market & Valuation
Market Cap	$43M	$38M
Enterprise Value	$38M	$-1M
Price	$1.27	$1.00
P/E Ratio	N/A	N/A
P/S Ratio	0.40x	2.72x
EV/Sales	0.00x	-0.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.01x	0.34x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.11x	0.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.83x
Revenue & Growth
Revenue (TTM)	$0	$14M
Revenue Growth (YoY)	N/A	-50.7%
Forward Rev Growth	0.0%	30.0%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	34.9%	0.0%
EBITDA Margin (TTM)	0.0%	-491.3%
Net Margin (TTM)	39.0%	-477.5%
FCF Margin (TTM)	N/A	-620.9%
Net Income (TTM)	$-34M	$-66M
FCF (TTM)	$-9M	$-86M
EPS (TTM)	$0.00	$0.00
ROE (TTM)	-6886.0%	-5123.0%
ROA (TTM)	-6748.0%	-3662.0%
ROIC (TTM)	-6886.0%	-5123.0%
Financial Health
Cash	$6M	$39M
Debt	$0	$0
Net Cash/Debt	$6M	$39M
Current Ratio (TTM)	5.74x	4.50x
Quick Ratio (TTM)	5.34x	4.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.06	0.68
52W Performance	-49.2%	-68.7%
YTD Performance	-17.5%	-40.1%
% from 52W High	-57.2%	-74.7%
% from 52W Low	84.4%	4.2%
Efficiency & Yields
Asset Turnover (TTM)	0.84x	0.10x
FCF Yield (TTM)	-21.1%	-227.9%
Earnings Yield (TTM)	-79.7%	-175.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-671.6
EV/GP/RG	N/A	N/A
Ticker research	View LITS research	View MGX research